| Modulatory polynucleotides |
2023-6-08 |
2023-9-07 |
|
| regulatory polynucleotide |
2023-5-01 |
2023-6-22 |
|
| Amyotrophic Lateral Sclerosis (ALS) Treatment Compositions and Methods |
2023-4-17 |
2023-7-19 |
|
| regulatory polynucleotide |
2023-3-30 |
2023-6-06 |
|
| Huntington's Disease Treatment Compositions and Methods |
2023-3-27 |
2023-7-04 |
|
| Assays for the detection of AAV neutralizing antibodies |
2023-2-14 |
2023-3-09 |
|
| Aav capsid variants and uses thereof |
2023-2-07 |
2023-8-17 |
|
| Compositions and methods for delivery of aav |
2023-2-01 |
2023-4-12 |
|
| Baculovirus expression system |
2023-1-25 |
2023-8-03 |
|
| Closed-ended linear duplex dna for non-viral gene transfer |
2022-11-30 |
2023-2-16 |
|
| Compositions and methods for the treatment of tau-related disorders |
2022-11-17 |
2023-5-25 |
|
| Compositions and methods for treating amyotrophic lateral sclerosis and … |
2022-11-17 |
2023-5-25 |
|
| Aav capsid variants and uses thereof |
2022-11-16 |
2023-5-25 |
|
| Compositions and methods for the treatment of neurological disorders related to … |
2022-11-16 |
2023-7-13 |
|
| Redirection of aav capsid tropism |
2022-11-11 |
2023-1-26 |
|
| Aav capsid variants and uses thereof |
2022-11-01 |
2023-5-11 |
|
| Compositions and methods of treating huntington's disease |
2022-10-24 |
2022-12-01 |
|
| Tau binding compounds |
2022-10-13 |
2023-6-22 |
|
| Compositions and methods for the treatment of her2 positive cancer |
2022-9-19 |
2023-3-23 |
|
| Rescue of central and peripheral neurological phenotype of friedreich's ataxia … |
2022-9-13 |
2023-2-09 |
|
| Methods for biomedical targeting and delivery, and device and system for … |
2022-8-26 |
2022-11-22 |
|
| Compositions and methods of treating amyotrophic lateral sclerosis (als) |
2022-5-13 |
2022-7-01 |
|
| Modulatory polynucleotides |
2022-4-27 |
2022-7-20 |
|
| Compositions for the treatment of disease |
2022-4-26 |
2022-12-08 |
|
| Compositions for the treatment of disease |
2022-4-08 |
2022-12-15 |
|
| Treatment of amyotrophic lateral sclerosis (als) |
2022-3-22 |
2022-7-07 |
|
| Controlled expression of viral proteins |
2022-3-03 |
2023-1-12 |
|
| Controlled expression of viral proteins |
2022-3-03 |
2022-9-09 |
|
| Tau binding compounds |
2021-12-15 |
2022-10-16 |
|
| Regulatable expression using adeno-associated virus (aav) |
2021-12-06 |
2022-6-23 |
|
| Compositions and methods for the treatment of tauopathy |
2021-11-03 |
2022-5-12 |
|
| Compositions for the treatment of disease |
2021-8-26 |
2022-3-31 |
|
| Cell culture medium for use in producing gene therapy products in bioreactors |
2021-8-06 |
2023-6-14 |
|
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS RELATED TO … |
2021-7-26 |
2023-4-11 |
|
| Compositions and methods for the treatment of niemann-pick type c1 disease |
2021-7-26 |
2022-2-03 |
|
| Central nervous system targeting polynucleotides |
2021-7-01 |
2021-7-29 |
|
| Methods and systems for producing aav particles |
2021-7-01 |
2021-8-31 |
|
| Compositions and methods of treating neuropathic pain |
2021-6-04 |
2022-2-03 |
|
| Aav variants from second round libraries with tropism for central nervous … |
2021-5-05 |
2021-11-11 |
|
| Aadc polynucleotides for the treatment of parkinson's disease |
2021-5-03 |
2021-11-04 |
|
| AADC polynucleotides for the treatment of Parkinson's disease |
2021-4-19 |
2021-5-13 |
|
| Redirection of tropism of aav capsids |
2021-3-31 |
2023-4-27 |
|
| Methods and systems for producing aav particles |
2021-1-28 |
2023-8-03 |
|
| Systems and methods for producing gene therapy formulations |
2021-1-22 |
2021-3-01 |
|
| Vectorized editing of nucleic acids to correct overt mutations |
2020-9-03 |
2022-10-20 |
|
| Controlled expression of viral proteins |
2020-8-26 |
2021-3-04 |
|
| High-sensitivity immunoassay for the detection of frataxin in biofluids |
2020-8-11 |
2022-9-29 |
|
| Cell culture medium for use in producing gene therapy products in bioreactors |
2020-8-06 |
2021-2-18 |
|
| Aav variants with enhanced tropism |
2020-7-31 |
2021-2-11 |
|
| Compositions and methods for treating huntington's disease |
2020-7-24 |
2021-3-16 |
|
| COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
2020-7-24 |
2021-12-22 |
|
| Compositions and methods for the treatment of parkinson's disease |
2020-7-09 |
2021-1-14 |
|
| Compositions and methods for the vectored augmentation of protein destruction, … |
2020-5-07 |
2022-3-16 |
|
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAUPATHY |
2020-4-29 |
2022-8-31 |
|
| Treatment of amyotrophic lateral sclerosis and disorders associated with the … |
2020-4-29 |
2022-6-02 |
|
| Compositions and methods for the treatment of tauopathy |
2020-4-29 |
2020-11-05 |
|
| Systems and methods for producing baculoviral infected insect cells (biics) in … |
2020-4-29 |
2021-2-16 |
|
| Aav variants with enhanced tropism |
2020-4-29 |
2020-11-05 |
|
| VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
2020-4-29 |
2023-3-09 |
|
| Frataxin expression constructs having engineered promoters and methods of use … |
2020-1-20 |
2021-7-01 |
|
| Chimeric capsids |
2020-1-17 |
2020-5-14 |
|
| EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 … |
2019-10-15 |
2021-12-23 |
|
| Compositions and methods for delivery of aav |
2019-10-11 |
2021-12-02 |
|
| Engineered nucleic acid constructs encoding aav production proteins |
2019-10-04 |
2020-4-09 |
|
| Methods for measuring the titer and potency of viral vector particles |
2019-10-04 |
2021-11-11 |
|
| Redirection of tropism of AAV capsids |
2019-10-02 |
2021-5-13 |
|
| Frataxin expression constructs having engineered promoters and methods of use … |
2019-9-27 |
2021-12-23 |
|
| Aav variants with enhanced tropism |
2019-8-02 |
2020-2-06 |
|
| Treatment of amyotrophic lateral sclerosis and disorders associated with the … |
2019-7-02 |
2020-1-09 |
|
| Cannula system |
2019-7-02 |
2020-1-09 |
|
| Engineered 5' untranslated regions (5' utr) for aav production |
2019-6-13 |
2019-12-19 |
|
| Aav serotypes for brain specific payload delivery |
2019-5-16 |
2021-3-24 |
|
| Directed evolution of aav to improve tropism for cns |
2019-5-16 |
2019-12-26 |
|
| COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF AAV |
2019-5-15 |
2020-11-25 |
|
| Compositions and methods for the treatment of parkinson's disease |
2019-5-15 |
2021-7-01 |
|
| Compositions and methods for delivery of aav |
2019-5-15 |
2019-11-21 |
|
| Method for measuring efficacy of AADC viral vector |
2019-4-26 |
2021-2-02 |
|
| Insect cell manufactured partial self-complementary aav genomes |
2019-3-06 |
2019-9-12 |
|
| Delivery of central nervous system targeting polynucleotides |
2019-1-17 |
2019-11-08 |
|
| Compositions and methods for the treatment of aadc deficiency |
2018-11-02 |
2019-2-21 |
|
| Treatment of amyotrophic lateral sclerosis (als) |
2018-10-16 |
2023-2-01 |
|
| RESCUE OF FRIEDREICH CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM ATAXIA … |
2018-9-28 |
2020-1-29 |
|
| Compositions and methods of treating huntington's disease |
2018-9-21 |
2020-12-03 |
|
| COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF AAV |
2018-8-03 |
2020-1-08 |
|
| Trajectory array guide system |
2018-7-17 |
2019-1-24 |
|
| POLYNUCLEOTIDES OF AADC (L-AMINO ACID AROMATIC DECARBOXYLASE) FOR THE TREATMENT … |
2018-6-15 |
2019-10-23 |
|
| COMPOSITIONS AND TREATMENT METHODS FOR HUNTINGTON KOREA |
2018-5-04 |
2019-9-18 |
|
| MODULATING POLINUCLEOTIDES |
2018-5-04 |
2019-8-07 |
|
| Compositions and methods for the production of scaav |
2018-4-06 |
2018-8-24 |
|
| Regulatable expression using adeno-associated virus (aav) |
2016-2-23 |
2018-8-30 |
|